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ABSTRACT  Cancer-related inﬂammation has emerged in recent years as a major event contributing 
to tumor angiogenesis, tumor progression and metastasis formation. Bone marrow-derived and 
inﬂammatory cells promote tumor angiogenesis by providing endothelial progenitor cells that 
differentiate into mature endothelial cells, and by secreting pro-angiogenic factors and remodeling 
the extracellular matrix to stimulate angiogenesis though paracrine mechanisms. Several bone 
marrow-derived myelonomocytic cells, including monocytes and macrophages, have been identiﬁed 
and characterized by several laboratories in recent years. While the central role of these cells in 
promoting tumor angiogenesis, tumor progression and metastasis is nowadays well established, 
many questions remain open and new ones are emerging. These include the relationship between 
their phenotype and function, the mechanisms of pro-angiogenic programming, their contribution 
to resistance to anti-angiogenic treatments and to metastasis and their potential clinical use as 
biomarkers of angiogenesis and anti-angiogenic therapies. Here, we will review phenotypical and 
functional aspects of bone marrow-derived myelonomocytic cells and discuss some of the current 
outstanding questions.
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Introduction
Malignant transformation and tumor progression requires the 
cell to initiate sustained proliferation, escape endogenous cell-cycle 
control and DNA-damage checkpoints, evade external inhibitory 
factors and senescence and resist cell death. This is achieved 
by a combination of genetic and epigenetic events affecting the 
cancer cell itself, in particular the activation of oncogenes and 
immortalizing pathways and the inactivation of tumor suppressor 
and anti-apoptotic genes. In recent years, however, it became evi-
dent that in order to give rise to a clinically relevant tumor, cancer 
cells require support from the tumor microenvironment (Hanahan 
DQG :HLQEHUJ  5HVLGHQW VWURPDO ÀEUREODVWV LQÀOWUDWLQJ
LQÁDPPDWRU\FHOOVEORRGDQGO\PSKDWLFHQGRWKHOLDOFHOOVDUHWKH
main stromal cell populations contributing to tumor progression 
(Lorusso and Rüegg, 2008). The formation of a tumor-associated 
vasculature, a process also referred to as tumor angiogenesis, 
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</.`\ZIV[NWZUQVOOZW_\PNIK\WZJM\I#<4:\WTTTQSMZMKMX\WZ#<6.\]UWZ
VMKZW[Q[ NIK\WZ# ]8) ]ZWSQVI[M\aXM XTI[UQVWOMV IK\Q^I\WZ >-/. ^I[K]TIZ
MVLW\PMTQITOZW_\PNIK\WZ#>-/.:^I[K]TIZMVLW\PMTQITOZW_\PNIK\WZZMKMX\WZ
is essential to tumor growth and progression. The initiation of 
tumor angiogenesis (an event also referred to as the angiogenic 
switch) is determined by the balance between the genetic status 
of the tumor itself (e.g. loss of p53, Ras activation), signals from 

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WKHPLFURHQYLURQPHQWHJLQÀOWUDWLQJLQ-
ÁDPPDWRU\FHOOVDQGE\WKHDSSHDUDQFH
of tumor hypoxia (Kerbel, 2008). Many 
molecular mediators and regulators of 
angiogenesis have been in elucidated in 
recent years, but our understanding of the 
functional relationship between angioge-
nic vessels and the cellular elements of the 
tumor microenvironment has remained 
OLPLWHG &DQFHU DVVRFLDWHG ÀEUREODVWV
LPPXQHLQÁDPPDWRU\ FHOOV DQG ERQH
marrow-derived cells present in the tumor 
microenvironment concur to promote and 
regulate to tumor angiogenesis (Lorusso 
and Rüegg, 2008). 
Bone marrow-derived cells 
promoting tumor angiogenesis
Over the past decade, efforts have 
been undertaken to phenotypically and 
functionally characterize bone marrow-
derived (BMD) cells recruiting to the tumor 
microenvironment and promoting tumor 
angiogenesis. Functional experiments 
have been performed in mice and corre-
lative studies in human. The phenotypical 
and functional plasticity, two main features 
intrinsically associated with the nature 
of these cells, make these study and 
the interpretation of the results complex. 
While tumor-mobilized myelomonocytic BMD cells have been 
globally considered to exert pro-angiogenic activities, one of the 
PDLQFKDOOHQJHVLQWKHÀHOGLVWRFRUUHODWHLQGLYLGXDOSKHQRW\SHVZLWK
VSHFLÀFIXQFWLRQDOSURSHUWLHV0DQ\H[FHOOHQWUHYLHZVGLVFXVVLQJ
BMD cell populations and their role in angiogenesis have been 
SXEOLVKHGUHFHQWO\+HUHZHZLOOVSHFLÀFDOO\DGGUHVVSKHQRW\SLFDO
functional aspects associated with myelomonocytic CD11b+ BMD 
cells mobilized by and recruited to tumors. 
Phenotypic heterogeneity of monocytes and tumor 
associated macrophages
Monocytes are released from bone marrow into the circulation 
and differentiate into macrophage at tissue sites. Macrophages 
present in the tumor microenvironment are referred to as tumor 
associated macrophages or TAM (Coffelt et al., 2010; Mantovani 
et al., 2008; Murdoch et al., 2008) (Fig. 1). Monocytes can be clas-
VLÀHGDVUHVLGHQWDQGLQÁDPPDWRU\VXEVHWVLQPRXVHDQGKXPDQ
5HVLGHQWPRQRF\WHVDUHIRXQGLQERWKUHVWLQJDQGLQÁDPHGWLVVXHV
and express the chemokine receptor CX3CR1, the integrin LFA-1 
(_L`2), but lack expression of Ly6C, CCR2 and L-selectin. Resident 
monocytes patrol blood vessels, promote tissues remodeling and 
might differentiate into pro-angiogenic macrophages. One particular 
subset of circulating monocytes promoting tumor angiogenesis 
is the Tie2-expressing monocyte subset, or TEM (De Palma et 
al.  ,QPRXVH WXPRULQÀOWUDWLQJ7(0DUH&'+CD11b+. 
Human TEM have been described as CD11b+, CD11c+, CCR2-, 
CCR5+ and CD62L-VXEVHWVRI&'+&'lowCD16+ monocytes. 
Fig. 1. Phenotypical characteristics of bone marrow-derived myelomonocytic cells and mac-
rophages in cancer. This ﬁgure summarizes the main bone marrow-derived myelomonocytic and 
macrophage populations mobilized and recruited by tumors. These phenotypes are not deﬁnitive as the 
characterization of many of the cells is still ongoing. Abbreviations: MDSC, myeloid –derived suppres-
sor cells; TAM, tumor-associated macrophages; TEM, Tie-2 expressing monocytes. Based on (Coffelt 
et al., 2010; De Palma et al., 2005; Gabrilovich and Nagaraj, 2009; Mantovani et al., 2008; Murdoch et 
al., 2008; Murdoch et al., 2007; Passlick et al., 1989; Pollard, 2009) and references herein.
Angiogenesis-associated BMD cells have heterogeneous and 
in part overlapping phenotypes while they circulate in the blood 
and these phenotypes can be further modulated once the cells 
reach the tumor microenvironment. A further complication in the 
FKDUDFWHUL]DWLRQRI%0'LQÁDPPDWRU\FHOOVLVWKDWPDUNHUVXVHG
WRSKHQRW\SLFDOO\GHÀQHWKHVHFHOOVGLIIHUDWOHDVWLQSDUWLQKXPDQ
and mice. Depending of their activating stimuli, recruited BMD 
DQGLQÁDPPDWRU\FHOOVPD\KDYHDQWLWXPRURUWXPRUSURPRWLQJ
effects. Several different BMD cell populations contributing to tu-
mor angiogenesis have been characterized (Coffelt et al., 2010; 
Murdoch et al., 2008).
i) Endothelial cell progenitors, which incorporate into the vas-
culature and differentiate into mature endothelial cells. &'-; 
CD133+&'+&'-.
ii) VEGFR-1+CD11b+ myelomonocytic cells that accumulate at 
tumor sites and contribute to tumor angiogenesis in a VEGFR-
1-dependent manner;
iii) VEGFR-1+&;&5+CD11b+ myeloid cells, also referred to 
as recruited BMD circulating cells (RBCCs), that accumulate in 
response to VEGF expression; 
iv) Gr1+CD11b+ %0'FHOOVZKLFKZHUH LGHQWLÀHG DV DPDLQ
source of matrix metalloproteinase (MMP) -9;
v) Tie-2-expressing CD11b+ monocytes (TEM), which exert non-
redundant pro-angiogenic activity through paracrine mechanisms 
in mice and human;
vi) Pericyte precursors, which can differentiate into mature 
pericytes and stabilize nascent vessels. They are described as 
CD11b+, Sca-1+, PDGFR9+. 

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$VLPLODUSURÀOHKDVEHHQDVVRFLDWHGZLWKUHVLGHQWPRQRF\WHV,Q
PRXVHLQÁDPPDWRU\PRQRF\WHVDUHVHOHFWLYHO\UHFUXLWHGDWLQÁD-
med tissue (or lymph nodes) and express the cell surface protein 
Ly6C, which together with the related protein Ly6G forms the Gr1 
marker, the chemokine receptor CCR2 and the adhesion molecule 
/VHOHFWLQ&',QKXPDQWZRPRQRF\WHVXEVHWVFDQEHGHÀQHG
EDVHGRQ&'DQG&'H[SUHVVLRQ&'lowCD16+ monocytes, 
sharing a phenotype similar to that of resident mouse monocytes 
DQG &'+CD16- PRQRF\WHV UHVHPEOLQJ PRXVH LQÁDPPDWRU\
monocytes (Passlick et al., 1989). 
Recently, a CD11c+HLA-DR+ monocytic population termed vas-
cular leukocytes, was reported to assemble into blood vessels in 
vivo expressing both endothelial and leukocytic/monocytic markers, 
LQFOXGLQJ&', VE cadherin and Tie2 (Murdoch et al., 2008). The-
se observations raise the question of whether distinct monocyte/
macrophage subsets found in tumors represent distinct lineages or 
are rather different differentiation states originated from a common 
progenitor cell. )RUH[DPSOHLQWKHPRXVHWXPRULQÀOWUDWLQJ7LH
expressing monocytes and blood-circulating resident monocytes 
share gene expression gene signatures suggesting common deve-
lopmental relationships and shared functions (Pucci et al., 2009).
7$0ZHUHDPRQJWKHÀUVWLGHQWLÀHGWXPRULQÀOWUDWLQJOHXNRF\WHV
DQGDUHQRZWKHEHVWFKDUDFWHUL]HGRQHV7$0DUHRIWHQLGHQWLÀHG
E\WKHH[SUHVVLRQRI&'EDQGRU)LQPRXVHDQG&'LQ
human (Mantovani et al., 2008). Increased frequency of CD68+ 
TAM correlates with an increase in tumor vascularisation in human 
tumors. Monocytes/macrophages and their progenitors may also 
H[SUHVV9(*)5&;&5RU&'([SUHVVLRQRIFODVVLFDOPRXVH
macrophage marker can be modulated by activation. Macrophages 
in response to environmental signals have been divided in M1 
(classical activation) and M2 (alternative activation) subsets (Man-
tovani et al.0PDFURSKDJHVSRVVHVVSURSURLQÁDPPDWRU\
and cytotoxic activities, while M2 macrophages are considered as 
immunosuppressive and pro-angiogenic macrophages. The role 
of TAM in tumor angiogenesis was demonstrated by many diffe-
rent experimental approaches and is nowadays well established. 
Besides promoting angiogenesis, a subset of myeloid cells can 
facilitate tumor growth and metastasis trough direct trophic or 
paracrine mechanisms (Pollard, 2009). 
Myeloid-derived suppressor cells (MDSC)
A particular class of BMD myeloid cells consists of cells with 
immunosuppressive functions also called myeloid-derived suppres-
sor cells (MDSC) (Gabrilovich and Nagaraj, 2009). MDSC are a 
SKHQRW\SLFDOO\KHWHURJHQHRXVFHOOSRSXODWLRQJOREDOO\GHÀQHGLQ
mice by the expression of CD11b and Gr1. This is a rather reductive 
GHÀQLWLRQVLQFHDGGLWLRQDOGLIIHUHQWVXUIDFHPDUNHUVKDYHEHHQ
associated with immunosuppressive activity of MDSC, including 
CD80, CD115 (macrophage colony-stimulating factor receptor) or 
&',/UHFHSWRUDOSKDFKDLQ0RUSKRORJ\KDVDOVREHHQXVHG
WRFKDUDFWHUL]HPRXVH0'6&0RQRQXFOHDU0'6&DUHGHÀQHG
as monocytic MDSC and are CD11b+Ly6G-Ly6Chigh, whereas cells 
ZLWKPXOWLOREHGRUVHJPHQWHGQXFOHLDUHGHÀQHGDVJUDQXORF\WLF
neutrophil-like MDSC and are CD11b+Ly6G+ly6Clow (Youn et al., 
2008) in the mouse and CD11b+&'-CD33+ HLA-DR- in human 
(Ochoa et al., 2007). 
Other types of cells, including neutrophils, eosinophils or dendritic 
cells may also express many of these markers and are reported 
to promote tumor angiogenesis (Coffelt et al., 2010; Murdoch et 
al., 2008)
Functional characterization of myeloid bone marrow-
derived cells in tumor angiogenesis
Tie2 expressing monocytes (TEM)
The close proximity of TEM to the tumor vasculature observed 
by De Palma and colleagues, suggested that TEM might contribute 
to the regulation of tumor angiogenesis. Selective depletion of TEM 
by a suicide gene approach in mouse tumor models resulted in 
reduced tumor angiogenesis without impact on the recruitment 
of TAM or neutrophils (De Palma et al., 2005). This observation 
suggested that TEM are a sub-population of monocytes distinct 
from precursors of TAM. It was suggested that TEM stimulate 
angiogenesis by expressing the pro-angiogenic molecule bFGF 
(De Palma et al., 2005). Angiogenic activity of TEM may also be 
modulated by hypoxia and other cues, in particular angiopoietin-2. 
Exposure to both hypoxia and angiopoietin-2 markedly suppresses 
the release of the potent anti-angiogenic cytokine IL-12 by human 
TEM, and the combined action of angiopoietin-2 and hypoxia inhi-
ELWHGWKHUHOHDVHRIWXPRUQHFURVLVIDFWRU71)DQLQÁDPPDWRU\
cytokines with context-dependent pro- or anti-angiogenic activities 
(Murdoch et al., 2007) (Fig. 2).
Tumor-associated macrophages (TAM)
Whereas M1 macrophages are thought to suppress tumor growth 
by secreting cytotoxic agents, such as TNF, IL-12, reactive nitrogen 
(iNOS) and reactive oxygen species (ROS) (Sica et al., 2008), M2 
macrophages are considered to promote tumor growth. M2 ma-
crophages release a number of potent pro-angiogenic cytokines, 
such as VEGF-A, VEGF-C, TNF, IL-8 and bFGF and suppress the 
immune response through the secretion of immunosuppressive 
cytokines, including IL-10 and transforming growth factor (TGF-
9) (Sica et al., 2008). Additionally, TAM secrete a large panel of 
proteases, including urokinase-type plasminogen activator (uPA), 
members of the matrix metalloproteinase family (MMP-2, -7, -9 
and -12) and elastases, which can contribute to the angiogenic 
switch. In vitro, TAM express additional pro-angiogenic factors like 
interleukin-19 and cyclooxygenase-2 (COX2) (Dirkx et al., 2006). 
Tumor hypoxia plays an important role in modulating TAM activity. 
TAM accumulate in hypoxic and peri-necrotic tumor regions. Hypoxic 
macrophages up-regulate hypoxia-inducible transcription factors 
(HIF) resulting in the increased transcription of a large panel of 
genes that regulate cell survival, cell metabolism and angiogenesis, 
including hepatocyte growth factor (HGF), VEGF, bFGF, tissue 
factor (TF) or MMP-12 (Dirkx et al., 2006) (Fig. 2). 
Myeloid-derived suppressor cells (MDSC)
0'6&DUHGHÀQHGE\WKHLUDELOLW\WRVXSSUHVVLPPXQHUHVSRQVHV
in particular T lymphocyte activation, in vitro and in vivo (Gabrilovich 
and Nagaraj, 2009). Several mechanisms have been proposed 
to explain this immunosuppressive effect, including release of 
cytokines and nitric oxide (NO), generation of reactive oxygen 
species (ROS), and increase activity of L-arginase (Kusmartsev 
and Gabrilovich, 2006). Cytokine-mediated immunosuppression 
involves MDSC-mediated increased production of type 2 cytokines 
by macrophages, such as IL-10 and TGF-`, and the down-regulation 
of the production of type 1 cytokines such as IL-12, thereby promoting 
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the emergence of a M2 tumor-promoting phenotype. Furthermore, 
MDSC can produce TGF-` in response to IL-13 stimulation, which 
further reduces the cytotoxic activity of T-cells. MDSC also express 
several factors with direct tumor-promoting activity, such as IL-6, 
platelet-derived growth factor (PDGF) or granulocyte macrophage 
colony-stimulating factor (GM-CSF) (Sauer et al., 2001). Arginase, 
inducible NO synthase (iNOS), ROS and COX-2 have been shown 
to play a critical role in mediating the immuno-suppressive activity 
of the MDSC (Gabrilovich and Nagaraj, 2009). Indeed, T-cell pro-
liferation and activation depends on the availability of L-arginine 
which is the substrate for two enzymes, the inducible iNOS and 
arginase-I. MDSC express both enzymes at high levels (Gabrilo-
vich and Nagaraj, 2009) resulting in a depletion of L-arginine in 
the microenvironment and consequently in an inhibition of T-cell 
function. ROS contribute to the immune tolerance of cytotoxic 
CD8 T-cells by altering antigen recognition (Nagaraj et al., 2007). 
COX-2 is a key factor promoting the activation of MDSC and in 
regulating the expression of arginase-1 and iNOS. COX-2 media-
tes the production of prostaglandin E2 (PGE2), a potent positive 
regulator of tumor angiogenesis (Gabrilovich and Nagaraj, 2009). 
Thus, COX-2 coordinates the suppressive activity of MDSC and 
angiogenesis in the tumor microenvironment (Fig. 2).
Other myeloid cell subpopulations
While many studies have analyzed the role of TAM, MDSC and 
TEM in tumor angiogenesis, additional myeloid-derived cell popu-
lations may also contribute to this process, including neutrophils, 
eosinophils, mast cells and dendritic cells (DC) (Coffelt et al., 2010). 
For some of these cells, the mechanism by which they mediate 
or modulate tumor angiogenesis has been addressed, and in part 
elucidated, while for others it remains elusive. Tumor-associated 
neutrophils are a major source of MMP9, along with macrophages 
or mast cells, and appear to promote angiogenesis by releasing 
matrix-sequestered angiogenic factors, such as VEGF. Alternatively, 
they may themselves release VEGF via a degranulation process 
LQGXFHGE\LQÁDPPDWRU\VWLPXOLVXFKDV71)5HFHQWO\LWKDVEHHQ
postulated that similarly to TAM, tumor-associated neutrophils can 
be polarized in the tumor environment into N1 or N2 phenotypes, 
the latter being associated to a tumor-promoting activity. TGF-` has 
EHHQLGHQWLÀHGDVDIDFWRUSURPRWLQJWKLVSRODUL]DWLRQ)ULGOHQGHU 
et al., 2009). Eosinophils and mast cells can release factors like 
bFGF, IL-6, IL-8, PDGF, TNF, TGF-` and matrix-modifying protea-
ses, in particular MMP9, with pro-angiogenci properties (Crivellato 
et al., 2008). In eosinophils, VEGF secretion is observed shortly 
after IL-15 stimulation. DC are considered to play an important role 
LQ WXPRU LPPXQRVXUYHLOODQFHE\HOLFLWLQJ WXPRUVSHFLÀF7FHOOV
responses. Recent evidence, however, indicates that DC might 
also contribute to tumor angiogenesis by releasing proangiogenic 
factors, like VEGF and IL-8, in response to hypoxia (Ricciardi et al., 
2008). Human tumor cells implanted together with immature DC 
have enhanced tumor vascularization and growth, while mature 
DC did not impact angiogenesis (Fig. 2).
These observations, together with the intrinsic plasticity of BMD 
DQGLQÁDPPDWRU\FHOOVLQUHVSRQVHWRPLFURHQYLURQPHQWDOFXHV
and the persistence of polarizing signals in the tumor microenvi-
URQPHQWVXJJHVWWKDWPDQ\LIQRWDOO%0'DQGLQÁDPPDWRU\FHOOV
reaching the tumor microenvironment might eventually produce pro-
angiogenic and pro-invasive factors promoting tumor progression. 
Mobilization and recruitment of bone marrow-derived 
myeloid cells into tumors
Recruitment of BMD myeloid cells is a highly regulated process 
depending of chemo-attractant factors. CCL2, also known as mo-
nocyte chemotactic molecule-1 (MCP-1) and CCL5, also known as 
RANTES, are well-established chemo-attractants for myeloid cells 
%DONZLOO,QFUHDVHGOHYHOVRIWKHVHFKHPRNLQHVOHDGWRDQ
LQFUHDVHGLQÀOWUDWLRQRI7$07FHOOVDQGHRVLQRSKLOVLQWRSULPDU\
tumors. The HIF-1-dependent chemokine CXCL12 (also known as 
stromal cell-derived factor-1, SDF-1), a ligand for the chemokine 
UHFHSWRU&;&5SURPRWHVWXPRUDQJLRJHQHVLVWKRXJKWKHPREL-
OL]DWLRQDQGUHFUXLWPHQWRI&;&5+VEGFR1+ hemangiocytes (Jin 
Fig. 2. Tumor-promoting effects of bone 
PDUURZGHULYHGDQGLQÁDPPDWRU\FHOOV 
This scheme summarizes the main bone 
marrow-derived and inflammatory cells 
present in the tumor microenvironment, 
which promote tumor angiogenesis, tumor 
proliferation, survival and invasion and 
suppress the speciﬁc anti-tumor immune 
response of CD4 and CD8 lymphocytes. 
Selected factors mediating these effects 
are indicated. Abbreviations: DC, dendritic 
cells; MDSC, myeloid-derived suppressor 
cells; TAM, tumor-associated macrophages; 
TEM, Tie-2 expressing monocytes.
et al., 2006). Interleukin-8 (IL-8), VEGF, 
PDGF and colony-stimulating factor-1 
(CSF-1) produced by various types of tu-
mors, are also potent chemo-attractants 
for monocytes/macrophages. Other 
cytokines like IL-19 and `-defensin 
may also serve as recruitment factors 
for neutrophils, macrophages and DC 
(Conejo-Garcia et al.5HFHQWO\
SURNLQHWLFLQ RU %Y ZDV LGHQWLÀHG

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(IL-10high/Il-12low). Nuclear overexpression of the p50 subunit 
resulted in the inhibition of NF-g%GHSHQGHQW SURLQÁDPPDWRU\
genes including TNF and IL-12 (Saccani et al., 2006). However, 
7$0IURPSGHÀFLHQWPLFHUHJDLQHGDSURLQÁDPPDWRU\0
phenotype with reduced tumor growth attributed to restored NF-gB 
activity (Saccani et al., 2006). Another group showed that IKK`/
NF-gB activation was required to maintain the M2 TAM phenotype 
in a model of ovarian cancer. Many different cell surface receptors 
expressed in macrophages lead to the activation of the NF-gB 
pathway, including toll-like receptor (TLR), IL-1 receptor (IL-1R) and 
TNF receptor 1 (TNFR-1) (Karin et al., 2006). For example, IL-19 
induces the production of tumor-promoting factors, including VEGF, 
IL-6 and TNF in co-cultures of macrophages and B16 melanoma 
cells via NF-gB. In an ovarian cancer model, macrophages from 
,/5GHÀFLHQWPLFHIDLOHGWRSURPRWHWXPRUJURZWKVXJJHVWLQJ
DQLPSRUWDQWUROHRI,/VLJQDOLQJ$FWLYDWLRQRI75/ZLWKOLSRSR-
lysaccharide (LPS) in a murine cancer metastasis model induced 
a NF-gB activation and secretion of TNF by myeloid cells resulting 
in increased metastasis formation. Recently, Kim et al., showed 
that activation of TLR2 and TLR6 (receptors for Gram-positive 
bacteria-derived lipoteichoic acid and lipoprotein, respectively) by 
the proteoglycan versican up-regulated in many human tumors, 
induced TNF secretion by myeloid cells and increased metastasis 
in a Lewis lung carcinoma model (Kim et al., 2009). Further stu-
dies are necessary to investigate which factors and pathways are 
critically involved in the long-term maintenance of M2 phenotype 
of TAM and their pro-tumoral activities.
Therapeutic implications
7KH VWURQJ DVVRFLDWLRQ EHWZHHQ LQÁDPPDWLRQ DQG FDQFHU
VXJJHVWVWKDWWUHDWPHQWVWDUJHWLQJP\HORPRQRF\WLFLQÁDPPDWRU\
FHOOVPD\KDYHSRWHQWLDOEHQHÀFLDOWKHUDSHXWLFHIIHFWVLQFDQFHU
6HYHUDOPROHFXOHVDQGSDWKZD\VKDYHEHHQLGHQWLÀHGDQGWDUJHWHG
in preclinical models and clinical studies (Fig. 3).
COX-2
There is solid epidemiological evidence demonstrating that the 
UHJXODU XVH RI QRQVWHURLGDO DQWLLQÁDPPDWRU\ GUXJV 16$,'V
reduces the risk of developing cancers, in particular colorectal 
cancer (Ulrich et al., 2006). The use of NASAIDs leads to a signi-
ÀFDQWUHGXFWLRQLQWKHQXPEHURIFRORUHFWDOSRO\SVLQSDWLHQWVZLWK
familial adenomatous polyposis coli (APC), thereby decreasing the 
risk for progression to carcinoma (Steinbach et al., 2000). These 
effects have been attributed to the inhibition of COX-2, the indu-
FLEOHSURLQÁDPPDWRU\F\FORR[\JHQDVHLVRIRUPKLJKO\H[SUHVVHG
LQWXPRUV:KLOHWKHVHÀQGLQJVSURYLGHDSURRIRISULQFLSOHWKDW
WKHLQKLELWLRQRIWXPRUDVVRFLDWHGLQÁDPPDWLRQVXSSUHVVHVWXPRU
progression, the sustained inhibition of COX-2 activity in patients 
was associated with severe cardiovascular and thromboembolic 
complications and the notion of using COX-2 inhibitors for long-
term treatment for cancer prevention was abandoned. Alternative 
WKHUDSHXWLFDSSURDFKHVWDUJHWLQJFDQFHUUHODWHGLQÁDPPDWLRQDQG
LQÁDPPDWRU\FHOOVQHHGWREHSXUVHG
Tumor necrosis factor (TNF)
There is a clear association between TNF expression and risk 
of cancer development and progression (Balkwill, 2009). Genetic 
or pharmacological inhibition of TNF suppresses the development 
as a critical regulator of CD11b+Gr1+ cell mobilization from the 
bone marrow, and CD11b+Gr1+ cell-mediated tumor angiogenesis 
(Shojaei et al., 2008). Anti-Bv8 antibody treatment resulted in a 
VLJQLÀFDQWGHFUHDVHRIWXPRUJURZWKDQGDUHGXFWLRQLQ&'E+Gr1+ 
cell mobilization from the bone marrow. Placenta growth factor 
(PlGF), a VEGF-family member binding only to VEGFR-1, has 
been reported to contribute to the recruitment of myeloid cells 
into the tumor microenvironment (Fischer et al., 2007). Blocking 
PlGF results in the inhibition of monocyte/macrophage recruitment 
to tumor sites, reduced tumor angiogenesis and tumor growth, 
in particular in combination with anti-VEGF therapy (Fischer et 
al., 2007). The role of PlGF in tumor angiogenesis, and its value 
as potential therapeutic target, however, is matter of controversy 
(Bais et al., 2010; Van de Veire et al., 2010). Of interest, inhibition 
of PlGF activity results in reduced formation of lung metastases 
(Bais et al., 2010). MMP-9, besides being an essential mediator of 
the angiogenic switch through the release of matrix-bound VEGF 
at tumor sites, can also promote BMD cell mobilization though 
the release of c-Kit ligand (or stem cell factor) form bone marrow 
stromal cells (Heissig et al., 2002). CSF-1 was reported to be a 
critical factor promoting breast cancer growth and metastasis by 
attracting monocytes to the turmor (Lin et al., 2001). A selective 
small molecule kinase inhibitor of CSF1R (GW2580) in combination 
with the anti-VEGFR-2 antibody DC101 suppresses tumor growth 
YLDUHGXFHGUHFUXLWPHQWDQGDWWHQXDWHGIXQFWLRQRIWXPRULQÀOWUDWLQJ
myeloid cells (Pollard, 2009).
Regulation of activation of tumor-recruited bone 
marrow-derived myeloid cells
Hypoxia
One common condition present in solid tumor is hypoxia (ge-
nerally < 1% pO2). Tumor cells exposed to hypoxia, adapt their 
activities by expressing genes promoting glycolytic metabolism, 
angiogenesis, cell motility, invasion and metastasis. Many of these 
adaptive responses are regulated by hypoxia-inducible factors 
(HIFs) (Giaccia et al.+,)VDUH_/` heterodimeric trans-
cription factors whose _ subunit is degraded in the presence of 
oxygen by prolyl hydoxylases (PHDs) -mediated hydroxylation and 
targeting to the proteasome (Giaccia et al.+,)UHJXODWHV
the expression of many genes promoting angiogenesis including 
VEGF, PDGF-9, bFGF, eNOS, PlGF, angiopoietin-2. In addition HIF 
regulates the expression of chemo-attractant factors (i.e. MCP-1, 
CSF-1, SDF-1) to recruit myeloid cells into tumor hypoxic areas 
(Liao and Johnson, 2007). 
,QÁDPPDWRU\VLJQDOLQJSDWKZD\V
Macrophage activation depends on signals originating from 
the surrounding microenvironment. The NF-gB pathway is a key 
mediator of macrophage activation in response to diverse envi-
ronmental stimuli (i.e. stress, infections) and cancer (Karin and 
Greten, 2005). NF-gB activation in TAM shapes their pro-tumoral 
activities, including the release of TNF, IL-6 and IL-19, which sustain 
tumor cell growth or survival. Macrophages may change their pro-
tumoral phenotype depending of surrounding factors, tumor type, 
tumor stage, thereby contributing to the angiogenic switch. The 
role of NF-gB in the functional plasticity of TAM has been shown 
by several studies. Saccani et al., showed that defective of NF-gB 
function favored the induction of the M2 macrophage phenotype 
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of experimental tumors, including in the skin. TNF inhibitors, either 
VROXEOH7)15HWDQHUFHSWRUIXQFWLRQEORFNLQJDQWLERGLHVLQÁL[L-
mab), have entered clinical testing in multiple cancers, including 
ovary, breast and kidney. In these studies involving patients with 
advanced cancer, treatment was usually safe and well tolerated. 
There was evidence of biological activity of these TNF inhibitors 
ZLWK ELRPDUNHUV FRUUHODWLQJZLWK DQWLLQÁDPPDWRU\ DFWLYLW\ HJ
reduced CCL2 and IL-6 levels).
Interleukin-1 (IL-1)
IL-1 is also a potentially attractive target for anti-cancer thera-
pies as in some models it is clearly involved in tumor growth and 
SURJUHVVLRQPRVWO\ LQGLUHFWO\E\VWLPXODWLQJ LQÁDPPDWLRQ$SWH 
et al., 2006). Since IL-1 also stimulates the immune response, it 
could have dual, anti- and pro-tumoral effects. IL-1 is often highly 
expressed in solid tumors and polymorphism in the gene encoding 
IL-1Ra, the natural endogenous inhibitor of IL-1, is associated with 
susceptibility to some cancers, including of the bladder and colon. 
There is today increasing interest in inhibiting IL-1 as anti-cancer 
therapy and the availability of a clinically-approved IL-1 antagonist, 
anakinra may open the way to clinical studies aimed at testing this 
therapeutic opportunity (Dinarello, 2010).
CXCL12/CXCR4
,QKLELWLRQRIWKH&;&/6')UHFHSWRU&;&5ZLWKVPDOO
molecular antagonists or peptides (e.g. CTCE-9908, AMD3100, 
RCP169), resulted in reduced tumor growth and metastasis in 
several experimental models, including breast, prostate and brain. 
&;&5DQWDJRQLVWVV\QHUJL]HZLWKFKHPRWKHUDS\WRFRQWUROJOLRPD
growth (Redjal et al.&;&5LQKLELWLRQSUHYHQWHGDFFHOHUD-
ted tumor growth after chemotherapy by blocking the recruitment 
of mobilized endothelial progenitor cells and abrogated tumor re-
JURZWKDIWHUUDGLRWKHUDS\E\SUHYHQWLQJWKHLQÁX[RIYDVFXOJHQLF
CD11b+ BMD cells into irradiated tumors (Kioi et al., 2010). Thus, 
WKH 6')&;&5 D[LV LQ FRQVLGHUHG DQ LPSRUWDQW KXE LQ WKH
regulation of neo-vascularization during tumor growth (Petit et 
al.6LQFHD&;&5DQWDJRQLVWSOHUL[DIRULVQRZFOLQLFDOO\
available, one may consider the design of studies in patients with 
VROLGFDQFHUWHVWLQJWKHSRWHQWLDOEHQHÀWVRI&;&5LQKLELWLRQ
Zoledonate
Experimental evidence indicates that zoledronate and other 
nitrogen-containing bisphosphonates have anti-angiogenic pro-
perties. Their anti-angiogenic effects are in part mediated by direct 
action on endothelial cells. Treatment of endothelial cells with 
zoledronate reduced proliferation, survival, adhesion, migration 
and capillary-like tube formation in vitro and suppressed bFGF-
induced angiogenesis in vivo (Wood et al., 2002). We have shown 
that zoledronate acts on endothelial cells through the suppression 
of multiple, prenylation-dependent signaling pathways, including 
Ras-MAPK and PI 3K-Akt (Hasmim et al., 2007). In a transgenic 
mouse model of cervical cancer, zoledronate suppressed tumor 
angiogenesis and tumor progression by reducing MMP-9 expression 
in monocytes, resulting in decreased VEGF bioavailability (Giraudo 
et al.&OLQLFDOVWXGLHVKDYHSURYLGHGLPSRUWDQWHYLGHQFHWKDW
zoledronate and other nitrogen-containing bisphosphonates may 
Fig. 3. Therapeutic targeting of bone marrow-derived cells. There are currently several drugs approved 
for clinical use or in development that can be used to target bone marrow-derived and inﬂammatory 
cells present in the tumor microenvironments or factors derived thereof. Some of them, such the VEGF 
inhibitor bevacizumab, VEGFR inhibitors (e.g. sunitinib), epidermal growth factor receptor (EGFR) inhibi-
tors (such as the monoclonal antibody cetuximab, or the small kinase inhibitor erlotinib) are already in 
clinical use in oncology. Others, like the TNF inhibitor inﬂiximab or the IL-1 inhibitor anakinra are approved 
for non-oncological therapies and are now being tested as anti-cancer agents. Abbreviations: COXIB, 
COX2 inhibitors; DC, dendritic cells; MDSC, myeloid –derived suppressor cells; TAM, tumor-associated 
macrophages; TEM, Tie-2 expressing monocytes; TKI, tyrosine kinase inhibitors.
have anti-angiogenic effects in humans. 
Zoledronate treatment of cancer patients 
with bone metastases leads to a sustained 
reduction in serum levels of VEGF and 
PDGF. A transient reduction of circulating 
levels of bFGF and MMP-2 after zoledro-
nate infusion was also reported. We have 
UHFHQWO\REVHUYHGWKDWLQWKH7EUHDVW
tumor model, zoledronate treatments alte-
red the phenotype of circulating BMD cells, 
their recruitment to tumor and decreased 
tumor angiogenesis (Botta, manuscript 
in preparation). Since zoledronate and 
other aminobisphosphonates are widely 
used in the clinics in cancer patients (i.e. 
for bone metastases treatment in breast 
and prostate cancers), it will be important 
to design studies to further test their ability 
to impinge on BMD cell mobilization and 
recruitment to tumors.
Other drugs
7KHDQWLLQÁDPPDWRU\PROHFXOHWUDEHF-
tedin and linomide have been described 
WR VLJQLÀFDQWO\ UHGXFH WXPRU JURZWK E\
inhibiting pro-tumoral activity TAM and/
or impaired monocytes differentiation. 
Several existing anticancer agents such 
as paclitaxel have been proposed to act, at 
least in part, by inhibiting TAM recruitment 
and function.
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Outstanding questions
It is nowadays widely accepted that BMD myelomonocytic cells 
are mobilized and recruited by the tumor to promote tumor angio-
genesis and tumor progression. Many molecules and pathways 
LQYROYHG LQWKHVHHYHQWVKDYHEHHQ LGHQWLÀHGDQG LQYHVWLJDWHG
Possible therapeutic targets have been further studies and clini-
cal trials are underway to assess the feasibility of targeting BMD 
cells for therapeutic purposes in cancer. Nevertheless, a number 
of questions have remained unanswered, and novel ones are 
emerging. We would like to conclude by mentioning two questions 
of utmost clinical relevance: 
Where are BMD cells programmed to acquire pro-angiogenic 
activity? As mentioned above, the unraveling of the correlation 
between BMD cell phenotype and function remain key to the unders-
tanding of the functional biology of these cells. Are there committed 
BMD cell populations that once induced by tumor-derived signals 
develop into pro-angiogenic cells by activating pre-established pro-
JUDPV"2UDUHWKHUHVSHFLÀFWXPRUGHULYHGVWLPXOLWKDWHOLFLWVSHFLÀF
differentiation program giving rise to multiple phenotypically and 
functionally distinct sub-populations originating from one common 
BMD cell precursor? Where does this education take place? It is 
generally assumed that cells are mobilized from the bone marrow 
and educated in the tumor. This seems a logical interpretation of 
available experimental results. Aternatively it is possible that cells 
are programmed in the bone marrow to express pro-angiogenic 
activity and to acquire a give cell surface phenotype as they are 
mobilized from the bone marrow. This hypothesis, however, has 
not been thoroughly addressed yet. Such a possibility could have 
important implications to tumor biology and tumor progression, 
since programmed cells could reach distant organs with a fully 
active pro-angiogenic program and thereby possibly contributing to 
initiate angiogenesis at pre-metastatic sites or at sites of dormant 
metastases. Indeed CD11b+VEGFR-1+ myelomonocytic BMD cells 
have been reported to form the premetastatic niche, although their 
functional phenotype has not been investigated. If programming 
occurs before they form the pre-metastatic site, this could open 
the perspective of impinging on their angiogenic education before 
they reach the distant site. 
Can BMD myelomonocytic cells be used as surrogate markers 
of angiogenesis? To date there are no validated biomarkers of 
angiogenesis that can be applied in the clinic to quantify tumor 
DQJLRJHQHVLVLQLQGLYLGXDOSDWLHQWVDQGWRPRQLWRUHIÀFDF\RIDQWL
angiogenic treatments. Endothelial progenitor cells have been 
largely explored to this end (Sessa et al., 2008). In contrast, BMD 
myelomonocytic cells have not been thoroughly investigated to this 
end. We have initiated experiments to address this question and 
REVHUYHGVSHFLÀFSKHQRW\SLFDODQGIXQFWLRQDOFKDQJHVLQ&'E+ 
myelomonocytic cells in mice (Botta et al., manuscript in preparation) 
and in breast cancer patients (Laurent et al., 2011) compared to 
tumor-free mice and healthy donors, respectively. We have also 
DQDO\]HGWKHJHQHH[SUHVVLRQSURÀOHRIFLUFXODWLQJP\HORPRQRF\WLF
cells in tumor-free mice, tumor-bearing mice and tumor-bearing mice 
WUHDWHGZLWKDQWLDQJLRJHQLFGUXJVDQGREVHUYHGVSHFLÀFFKDQJHV
in gene expression (F. Botta et al., manuscript in preparation). A 
gene-expression-based approach to monitoring the angiogenic 
status of circulating myelomonocytic cells would be an attractive 
DOWHUQDWLYHWRFRPSOH[PXOWLFRORXUÁRZF\WRPHWU\EDVHGSURWRFROV
WRLGHQWLI\UDUHSRSXODWLRQZKRVHIXQFWLRQDOVLJQLÀFDQFHUHPDLQVWR
EHGHÀQHG&LUFXODWLQJP\HORPRQRF\WLFPD\HPHUJHDVFDQGLGDWH
biomarkers angiogenesis and anti-angiogenic therapies.
Conclusion
Since the original work published by the late Jeffry Isner in 1997 
and reporting progenitor endothelial cells released from the bone 
marrow and capable of promoting angiogenesis at distant sites 
(Asahara et al., 1997), we have gained a large amount of knowl-
edge on the role of BMD cells in promoting tumor angiogenesis 
DQGFDQFHUSURJUHVVLRQ7KHÀHOGKDVEHFRPHYHU\FRPSOH[DQG
FRQÁLFWLQJUHVXOWVZHUHVRPHWLPHVUHSRUWHG ,W LV LPSRUWDQW WKDW
among this wealth of information we ask the relevant questions 
to unravel key issues and to identify the critical factors that may 
eventually allow us to translate this knowledge into therapeutic 
strategies in patients. Close interactions between basic and pre-
clinical cancer researchers, clinical oncologists and industry will 
be necessary to reach this goal. 
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